Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0AZYWH
ADC Name	ZHER2:342-Cupid-His-Ax-SiPc
Synonyms	AMDCs; ZHER2:342 Cupid His Ax SiPc Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
	3D MOL	2D MOL
Antibody Name	ZHER2:342-Cupid-His		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Silicon Phthalocyanine		Payload Info
Linker Name	Psyche-Ax		Linker Info

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	82.4	%	KPL-4 cells	Breast inflammatory carcinoma
Tumor Growth Inhibition value (TGI)	93.4	%	KPL-4 cells	Breast inflammatory carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	82.40% (Day 21)	Low HER2 expression (HER2+)
Method Description	The Kadcyla (the anti- Her2 ADC) group were administered at 300 g.
In Vivo Model	KPL- 4 cell line xenograft model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.40% (Day 21)	Low HER2 expression (HER2+)
Method Description	The ZHER2:342-Cupid-His-Ax-SiPc group were administered at 150 g.
In Vivo Model	KPL- 4 cell line xenograft model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

References

Ref 1	Pathological complete remission of relapsed tumor by photo-activating antibody-mimetic drug conjugate treatment. Cancer Sci. 2022 Dec;113(12):4350-4362.